Senti Bio Showcases Logic-Gated Cell Therapy Approach at Cell & Gene Live
Event summary
- Senti Biosciences participated in the Cell & Gene Live virtual event on February 19, 2026.
- The event focused on technologies advancing cell therapy development, with Senti Bio highlighting its Gene Circuit platform.
- SENTI-202, a Logic Gated CAR-NK cell therapy targeting AML and MDS, was specifically mentioned.
- SENTI-202 has received Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
The big picture
Senti Bio's participation in Cell & Gene Live underscores the increasing focus on precision and control within the rapidly evolving cell therapy space. The company's Logic-Gated approach, exemplified by SENTI-202, represents a potential advancement over existing CAR-T therapies by targeting both leukemic blasts and stem cells while sparing healthy cells. The RMAT designation signals regulatory interest, but clinical trial results will be the ultimate arbiter of its success.
What we're watching
- Clinical Trial
- The success of the Phase 1 clinical trial for SENTI-202 will be critical in validating Senti Bio’s Logic-Gated approach and its potential to address unmet needs in AML and MDS.
- Competitive Landscape
- How Senti Bio’s Gene Circuit platform differentiates itself from other cell therapy approaches, particularly those utilizing CAR-T technology, will determine its long-term market share and pricing power.
- Manufacturing Scale
- The ability to scale off-the-shelf NK cell manufacturing for SENTI-202 and other potential therapies will be a key determinant of Senti Bio’s commercial viability and ability to meet patient demand.
Related topics